Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26 Week Treatment, Randomized, Multi Center, Double Blind, Double Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 microg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 microg b.i.d.) as an Active Control.

X
Trial Profile

A 26 Week Treatment, Randomized, Multi Center, Double Blind, Double Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 microg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 microg b.i.d.) as an Active Control.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 09 Jun 2012 Additional company (GlaxoSmithKline) added in association as reported by European Clinical Trials Database.
    • 22 Jul 2011 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top